Prostate Specific Membrane Antigen Targeted Positron Emission Tomography of Primary Prostate Cancer: Assessing Accuracy with Whole Mount Pathology

被引:15
作者
Bahler, Clinton D. [1 ]
Green, Mark [2 ]
Hutchins, Gary D. [2 ]
Cheng, Liang [3 ]
Magers, Martin J. [3 ]
Fletcher, James [2 ]
Koch, Michael O. [1 ]
机构
[1] Indiana Univ, Dept Urol, Indianapolis, IN 46204 USA
[2] Indiana Univ, Dept Radiol, Indianapolis, IN 46204 USA
[3] Indiana Univ, Dept Pathol, Indianapolis, IN 46204 USA
基金
美国国家卫生研究院;
关键词
prostatic neoplasms; positron-emission tomography; pathology; surgical; risk; early detection of cancer; RADICAL PROSTATECTOMY; GLEASON PATTERN-4; TUMOR VOLUME; MEN; PROGRESSION; BIOPSY; PERCENTAGE; PREDICTOR; PET/CT;
D O I
10.1097/JU.0000000000000501
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated which lesions are detected and missed on [Ga-68]Ga-PSMA (prostate specific membrane antigen)-11 positron emission tomography in patients with primary prostate cancer. Materials and Methods: Patients undergoing radical prostatectomy were enrolled in this prospective observational study. Patients underwent [Ga-68] Ga-PSMA-11 positron emission tomography/computerized tomography or positron emission tomography/magnetic resonance imaging prior to surgery and received a dose of [Ga-68] Ga-PSMA-11 intraoperatively for positron emission tomography of extirpated specimens. Whole mount pathology was performed with lesion and intralesion based analysis to determine the characteristics of lesions detected or not detected by PSMA positron emission tomography. Lesion volume was determined by planimetry and clinically significant lesion volume was calculated as lesion volume x fraction pattern 4/5. Results: On whole mount analysis 30 cancerous lesions were found in a total of 15 patients, including 4, 15, 4, 1 and 6 which were Grade Group 1, 2, 3, 4 and 5, respectively. PSMA-positron emission tomography detected 100% of primary/index lesions and 8 of 11 (82%) secondary lesions. All Grade Group 3-5 lesions were detected vs 12 of 15 Grade Group 2 lesions. When comparing Grade Group 2 vs 3-5, lesion size was similar (p = 0.48) but the standardized uptake value was lower for Grade Group 2 vs 3-5 (5.3 vs 7.9, p = 0.03). The 3 missed lesions showed 10% or less of pattern 4 and a Gleason pattern 4/5 volume of less than 0.1 cm(3). Conclusions: PSMA positron emission tomography detected 100% of primary/index lesions in this study. The 3 missed secondary lesions were small and had a low percent of pattern 4. This argues for further study to better understand what defines clinically significant prostate cancer, which would assist in determining whether small lesions that become challenging to detect by [Ga-68]Ga-PSMA-11 positron emission tomography confer a risk to the patient.
引用
收藏
页码:92 / 99
页数:8
相关论文
共 30 条
[11]   68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging [J].
Eder, Matthias ;
Schaefer, Martin ;
Bauder-Wuest, Ulrike ;
Hull, William-Edmund ;
Waengler, Carmen ;
Mier, Walter ;
Haberkorn, Uwe ;
Eisenhut, Michael .
BIOCONJUGATE CHEMISTRY, 2012, 23 (04) :688-697
[12]  
Eiber M, 2016, EUR UROL, V70, P1
[13]   IS TUMOR VOLUME AN INDEPENDENT PREDICTOR OF PROGRESSION FOLLOWING RADICAL PROSTATECTOMY - A MULTIVARIATE-ANALYSIS OF 185 CLINICAL STAGE-B ADENOCARCINOMAS OF THE PROSTATE WITH 5 YEARS OF FOLLOW-UP [J].
EPSTEIN, JI ;
CARMICHAEL, M ;
PARTIN, AW ;
WALSH, PC .
JOURNAL OF UROLOGY, 1993, 149 (06) :1478-1481
[14]   Prognostic Significance of Tumor Volume in Radical Prostatectomy and Needle Biopsy Specimens [J].
Epstein, Jonathan I. .
JOURNAL OF UROLOGY, 2011, 186 (03) :790-797
[15]   68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer [J].
Fendler, Wolfgang P. ;
Schmidt, Dorothea F. ;
Wenter, Vera ;
Thierfelder, Kolja M. ;
Zach, Christian ;
Stief, Christian ;
Bartenstein, Peter ;
Kirchner, Thomas ;
Gildehaus, Franz J. ;
Gratzke, Christian ;
Faber, Claudius .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (11) :1720-1725
[16]   Estimation of of radiation dosimetry for 68Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer [J].
Green, Mark A. ;
Eitel, Jacob A. ;
Fletcher, James W. ;
Mathias, Carla J. ;
Tann, Mark A. ;
Gardner, Thomas ;
Koch, Michael O. ;
Territo, Wendy ;
Polson, Heather ;
Hutchins, Gary D. .
NUCLEAR MEDICINE AND BIOLOGY, 2017, 46 :32-35
[17]   Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer [J].
Hicks, Robert M. ;
Simko, Jeffry P. ;
Westphalen, Antonio C. ;
Nguyen, Hao G. ;
Greene, Kirsten L. ;
Zhang, Li ;
Carroll, Peter R. ;
Hope, Thomas A. .
RADIOLOGY, 2018, 289 (03) :730-737
[18]   A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol [J].
Hofman, Michael S. ;
Murphy, Declan G. ;
Williams, Scott G. ;
Nzenza, Tatenda ;
Herschtal, Alan ;
De Abreu Lourenco, Richard ;
Bailey, Dale L. ;
Budd, Ray ;
Hicks, Rodney J. ;
Francis, Roslyn J. ;
Lawrentschuk, Nathan .
BJU INTERNATIONAL, 2018, 122 (05) :783-793
[19]   Targeted Prostate Biopsy to Select Men for Active Surveillance: Do the Epstein Criteria Still Apply? [J].
Hu, Jim C. ;
Chang, Edward ;
Natarajan, Shyam ;
Margolis, Daniel J. ;
Macairan, Malu ;
Lieu, Patricia ;
Huang, Jiaoti ;
Sonn, Geoffrey ;
Dorey, Frederick J. ;
Marks, Leonard S. .
JOURNAL OF UROLOGY, 2014, 192 (02) :385-390
[20]   Sample size of 12 per group rule of thumb for a pilot study [J].
Julious, SA .
PHARMACEUTICAL STATISTICS, 2005, 4 (04) :287-291